webinar register page

Discovery and Optimization of New Anti-migraine Peptides

The identification in recent years of the strong connection between neuroactive peptides and migraine has greatly incentivized further research and development of small protein molecules for treatment and prevention of this debilitating disorder. Correspondingly the demand for more efficient methods of purifying peptides has increased, especially in reversed phase chromatography, which has been shown to be very well suited to the task with excellent recovery and resolution. Reverse phase method development for this application, however, requires careful consideration of key parameters such as sample loading and stationary phase particle size.

Our featured guest speaker on this topic is Dr. Christopher R. Coxon, Institute of Chemical Sciences, School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh, UK. Dr. Coxon is also one of the co-authors of our Chromatography Application Note AN115: “Reversed Phase Flash Chromatography Purification of Peptide-Peptoid Hybrids.”

The moderator for this event is Josh Lovell, Applications Specialist at Teledyne ISCO, responsible for helping customers solve challenging problems in analytical, flash, and preparatory chromatography applications.

In this webinar Dr Coxon will discuss the latest treatments for migraine and the evidence showing peptides could be the best way forward. He will also describe his team’s work in discovering new treatments and how the latest peptide-related research technologies are being employed.

• Peptides as the future of migraine treatment and prevention
• Key considerations for the development and purification of peptide targets
• How reversed phase flash chromatography enables high resolution purification of
peptides where there are closely eluting impurities
• The right mobile phase for purifying peptides at high resolution
• Sample loading and stationary phase particle size considerations
• The role of Teledyne ISCO flash chromatography systems in this research

Apr 6, 2021 01:00 PM in Central Time (US and Canada)